# Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)

> **NCT03301506** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Gilead Sciences** · enrollment: 340 (estimated)

## Conditions studied

- Primary Biliary Cirrhosis

## Interventions

- **DRUG:** Seladelpar 5 mg Capsule
- **DRUG:** Seladelpar 10 mg Capsule

## Key facts

- **NCT ID:** NCT03301506
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-12-12
- **Primary completion:** 2028-11
- **Final completion:** 2028-12
- **Target enrollment:** 340 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03301506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03301506, "Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03301506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*